Phase 1b Dose Escalation and Dose Expansion Trial of DV281 in Combination With an Approved Anti-PD-1 Inhibitor in Subjects With Advanced Non-Small Cell Lung Cancer

Trial Profile

Phase 1b Dose Escalation and Dose Expansion Trial of DV281 in Combination With an Approved Anti-PD-1 Inhibitor in Subjects With Advanced Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs DV 281 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Dynavax Technologies
  • Most Recent Events

    • 03 Nov 2017 According to a Dynavax media release, the company has initiated dosing in this trial.
    • 19 Oct 2017 According to a Dynavax Technologies media release, Edward Garon, M.D., Associate Professor of Medicine at the David Geffen School of Medicine at UCLA is the primary investigator on the study.
    • 19 Oct 2017 Status changed from planning to recruiting, according to a Dynavax Technologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top